This presentation contains forward-looking statements, including forecasts of future revenue and operating profit, as well as expected business-related events. Such statements are subject to risks and uncertainties, as various factors, some of which are beyond ALK's control, may cause actual results and performance to differ materially from the forecasts made in this presentation. The coronavirus pandemic, and the extent and duration of countermeasures against the virus, represent additional uncertainties that may also affect forward-lookingstatements.
3 Webcast 9 May 2023
Overall results largely as expected
2023 full-year outlook unchanged
Tablet revenue DKK ~35 million lower than expected
o Mainly related to slightly fewer new patient initiations in Germany and the Nordics o As expected in North America and International markets
o Japan: Phasing of shipments; in-market sales growing in double digits
Sales in all regions expressed in DKK - Growth rates are in local currencies
5 Webcast 9 May 2023
Sales growth led by SCIT and Jext®
European SCIT sales rebounded, driven by venom products
Tablets
Share of Q1 revenue
47%
581m
+1%
583m
Q1-23
Q1-22
SCIT/SLIT-drops
Other products
Share of Q1 revenue
Share of Q1 revenue
12%
41%
483m
510m
143m
449m
+13%
123m
+14%
Q1-23Q1-22
Q1-23Q1-22
1,655m
+27%
Sales in all regions expressed in DKK - Growth rates are in local currencies
Attachments
Original Link
Original Document
Permalink
Disclaimer
ALK-Abelló A/S published this content on 09 May 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 May 2023 11:27:05 UTC.
ALK-Abello A/S is a Denmark-based company active within the pharmaceutical industry. It is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergy. Its product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. The Companyâs allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Its emergency treatments product offering comprises products for the management of anaphylaxis. Its allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests. The Company operates worldwide through subsidiaries, production units and distributors in such countries as Austria, Canada, France, Italy, the Netherlands, Poland, Spain, Switzerland, the United States and China.
ALK-ABELLÓ A/S 
